Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy-Reference-Cited by-同舟云学术

Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy

Published:2018-03 Issue:3 Volume:29 Page:737-743
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Friedlander M.,Rau J.,Lee C.K.,Meier W.,Lesoin A.,Kim J.-W.,Poveda A.,Buck M.,Scambia G.,Shimada M.,Hilpert F.,King M.T.,Debruyne P.,Bologna A.,Malander S.,Monk B.J.,Petru E.,Calvert P.,Herzog T.J.,Barrett C.,du Bois A.

Funder

NHMRC

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/3/737/24530914/mdx796.pdf

Reference21 articles.

1. Cancer statistics, 2015;Siegel;Cancer J Clin,2015

2. Incorporation of pazopanib in maintenance therapy of ovarian cancer;du Bois;J Clin Oncol,2014

3. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer;Berek;J Clin Oncol,2004